F. Hoffmann-La Roche, one of the world’s largest biotechnology companies, announced last week that it would more than triple ...

Through its Genentech subsidiary, the pharmaceutical company promises to further the Triangle's bona fides as a GLP-1 hotspot ...

Roughly half a year after breaking ground on the project, Roche is significantly upscaling its investment in a new production plant slated to come online in North Carolina’s biopharma hotbed. | Roche ...

Swiss pharma giant Roche’s RHHBY Genentech announced a significant expansion of its original investment in a new ...

Roche is a relative latecomer to GLP-1 metabolic disorder drugs, but an oral drug candidate that came as part of a $2.7 billion acquisition last year now has preliminary early-stage clinical data that ...

Genentech, a member of the Roche Group, plans to open the facility in 2029 to ramp up capacity to make obesity candidates, including the dual GLP-1/GIP receptor agonist CT-388.

If you are wondering whether Roche Holding is still an attractive opportunity after its recent run, or whether that value is already reflected in the price, this article will walk through what the ...

Under the agreement, MediLink will receive upfront and near-term milestone payments totalling $570m.

Ever wondered if Roche Holding is trading at a bargain or a premium? You are not alone, especially with all the chatter about big pharma valuations these days. The stock has shown some real momentum, ...

Roche's Gazyvaro, a drug that can restore kidney function in people living with lupus nephritis, has been cleared for use by ...

There isn’t a skin care brand that walks the tightrope between drugstore staple and universally trusted better than French ...

Roche has recently launched a “fundamental reorganization” of Spark Therapeutics, the gene therapy unit the Swiss pharma bought for $4.3 billion in 2019. Roche described the restructuring in its ...